Table 3 Prevalence of azithromycin-resistant (AzmR) and macrolide-inducible clindamycin resistant (iMLSB) S. aureus isolates over time and between treatment arms
Survey | Total | Resistant (%) | Crude OR (95% CI) | p-value | Adjusted ORa (95% CI) | p-value |
|---|---|---|---|---|---|---|
Overtime | ||||||
 AzmR | ||||||
  CSS-1 | 414 | 37 (8.9) | 1 |  | 1 |  |
  CSS-2 | 417 | 142 (34.1) | 5.26 (4.95–5.59) | <0.001 | 5.28 (4.95–5.64) | <0.001 |
  CSS-3 | 343 | 25 (7.3) | 0.80 (0.45–1.42) | 0.447 | 0.82 (0.47–1.42) | 0.471 |
 iMLSB | ||||||
  CSS-1 | 414 | 24 (5.8) | 1 |  | 1 |  |
  CSS-2 | 417 | 128 (30.7) | 7.20 (3.77–13.76) | <0.001 | 7.24 (3.72–14.1) | <0.001 |
  CSS-3 | 343 | 20 (5.8) | 1.01 (0.87–1.16) | 0.933 | 1.03 (0.90–1.17) | 0.673 |
Between treatment arms | ||||||
 AzmR | ||||||
  1× | 375 | 6 (1.6) | 1 |  | 1 |  |
  3× | 434 | 25 (7.3) | 4.83 (1.46–16.06) | 0.010 | 5.22 (1.49–18.34) | 0.010 |
 iMLSB | ||||||
  1× | 375 | 3 (0.8) | 1 |  | 1 |  |
  3× | 434 | 20 (5.8) | 7.68 (1.80–32.84) | 0.006 | 8.37 (1.89–37.14) | 0.005 |